NAVINFLUOR2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member NAVINFLUOR2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NAVINFLUOR 2020-04-01 2021-03-31 2020-12-30 INR Lakhs Third quarter Single segment Chemicals 2020-10-01 2020-12-31 Unaudited Standalone 2966286000.00 91072000.00 3057358000.00 1385770000.00 0.00 -26961000.00 293705000.00 2876000.00 101334000.00 490486000.00 2247210000.00 810148000.00 0.00 810148000.00 242083000.00 -18798000.00 223285000.00 0.00 586863000.00 0.00 0.00 0.00 0.00 586863000.00 -3925000.00 582938000.00 0.00 0.00 98988000.00 2 11.86 11.84 0.00 0.00 11.86 11.84 1.The results of the quarter ended and nine months ended 31st December 2020 were reviewed by the Audit Committee and approved by the Board of Directors of the Company, at its meeting held on 25th January, 2021. They have been subjected to limited review by the statutory auditors. n n2.During the quarter ended 31st December, 2020, the Company paid an interim dividend of Rs. 5 per share (250%) on 494,94,475 equity shares of nominal value of Rs. 2/- each, aggregating to Rs. 2,474.72 lakhs. n n3.On 28th October, 2020, the Board of Directors of the Company approved divestment of 49% stake (3,43,04,900 equity shares of face value Rs.10 each, which were subscribed at par) held in Convergence Chemicals Private Limited (‘CCPL’), for a consideration of Rs.6,510.00 lakhs to its JV partner Piramal Pharma Limited (‘PPL’); and also giving up lease rights in land earmarked for CCPL at GIDC, Dahej and sale of immovable assets standing thereon to CCPL for a consideration of Rs. 790.00 lakhs and Rs. 738.00 lakhs respectively.Subject to fulfilment of conditions precedent, the aforesaid transactions are expected to be completed by the year ending 31st March, 2021 and consequently, the JV Agreement with PPL will come to an end. n n4.The Company had contested receipts on account of Certified Emission Reduction (CER) as capital receipts not chargeable to tax from financial year 2007-08 to financial year 2012-13. During the year ended 31st March 2020, it received favourable appellate orders for some of the aforesaid years. This has resulted in the Company becoming liable to tax on its book profits for these years under section 115JB of the Income Tax Act, 1961 (the Act) [i.e. Minimum Alternate Tax (MAT)] and correspondingly eligible for MAT Credit in terms of section 115JAA of the Act, to be utilised against the tax liability of the succeeding years. Though the matter is contested by the tax authorities, considering the favourable pronouncements from various Tribunals/ High Courts in similar matters, including jurisdictional High Court and as legally advised, no outflow for the same is expected. nAccordingly, as at 31st March 2020, the Company had recognized MAT Credit entitlement of Rs. 7,355.19 lakhs under section 115JAA of the Act, for which claims have been made. The Company had recomputed the tax liabilities for these years and written back excess tax provisions amounting to Rs. 14,125.37 lakhs for earlier years. n n5.Other Income for the quarter ended 31st December, 2020 and nine months ended 31st December, 2020 includes interest of Rs. 88.20 lakhs and Rs. 2,705.86 lakhs respectively received on refund of income tax (corresponding quarter and nine months – Nil). n n6.The Company has identified Chemicals business as its only primary reportable segment in accordance with the requirements of Ind AS 108, ‘Operating Segments'. Accordingly, no separate segment information has been provided. n n7.Previous period’s figures have been regrouped, wherever necessary, to correspond to those of the current period. Single segment 2020-04-01 2020-12-31 Unaudited Standalone 8090681000.00 535321000.00 8626002000.00 3625846000.00 0.00 -48386000.00 867214000.00 8199000.00 300186000.00 1367113000.00 6120172000.00 2505830000.00 0.00 2505830000.00 804371000.00 -74341000.00 730030000.00 0.00 1775800000.00 0.00 0.00 0.00 0.00 1775800000.00 -8419000.00 1767381000.00 0.00 0.00 98988000.00 2 35.88 35.83 0.00 0.00 35.88 35.83 Other Expenses 490486000.00 Other Expenses 1367113000.00